We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
112
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
- Arna Pharma Inc. and Slate Run Pharmaceuticals have signed an MOU to create a U.S.-based specialty pharmaceutical joint venture focused on branded products, 505(b)(2) medicines, and specialized generics. - The partnership combines Arna Pharma's development capabilities with Slate Run's established U.S. commercial, regulatory, and supply chain infrastructure to accelerate market access and physician engagement. - Slate Run Pharmaceuticals currently markets more than 30 product families across multiple therapeutic areas, serving wholesalers, distributors, pharmacies, and healthcare providers throughout the United States. - The joint venture aims to expand specialized generics in high-value therapeutic segments while maintaining regulatory compliance and addressing unmet medical needs in rare and underserved diseases.
